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Purpose: Asymmetric dimethylarginine (ADMA), an endogenous competitive inhibitor of nitric oxide synthase, is
associated with impaired endothelial dysfunction, such as chronic heart failure, hypertension, diabetes, and pulmonary
hypertension. The effects of ADMA on cell proliferation, reactive oxygen species (ROS) production, cell permeability,
intercellular  adhesion  molecule-1  (ICAM-1),  and  tight-junction  protein  occludin  levels  in  bovine  retinal  capillary
endothelial cells (BRCECs) were investigated.
Methods: A cell proliferation assay was performed using the novel tetrazolium compound 3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium and an electron coupling reagent. Intracellular ROS levels
were determined using the fluorescent probe CM-H2DCFDA. Horseradish peroxidase was used for a permeability assay.
ICAM-1 and tight-junction protein occludin were assessed by western blotting and quantitative real-time PCR.
Results: Cell proliferation was significantly inhibited by ADMA. ADMA increased intracellular ROS generation in
BRCECs. The increased ROS production induced by ADMA was markedly inhibited by the angiotensin II receptor-blocker
telmisartan,  the  angiotensin-converting  enzyme  inhibitor  benazepril,  the  reduced  form  of  nicotinamide-adenine
dinucleotide phosphate (NADPH) oxidase inhibitor diphenyliodonium (DPI), or the antioxidant and free-radical scavenger
N-acetyl-L-cysteine (NAC). ADMA significantly increased horseradish peroxidase (HRP) permeability in BRCECs.
Benazepril,  telmisartan,  DPI,  and  NAC  downregulated  cell  permeability.  ADMA  markedly  upregulated  ICAM-1
expression in BRCECs, which were downregulated by telmisartan, DPI, and NAC. ADMA significantly downregulated
occludin expression in BRCECs. Benazepril and telmisartan upregulated occludin expression in BRCECs exposed to
ADMA.
Conclusions: Our results provide the first reported evidence that ADMA has potent adverse effects on cell proliferation,
intracellular ROS generation, cell permeability, levels of ICAM-1, and the tight-junction protein occludin. Angiotensin-
converting enzyme inhibitors, angiotensin II receptor blockers, and antioxidants are effective inhibitors of the adverse
effects of ADMA.
Asymmetric dimethylarginine (ADMA), an endogenous
competitive inhibitor of nitric oxide synthase, is generated in
the presence of type 1 protein arginine N-methyltransferase
(PRMT-1)  and  is  metabolized  by  dimethylarginine
dimethylaminohydrolases  (DDAHs)  [1].  Elevated  ADMA
concentration  in  plasma  is  associated  with  impaired
endothelial  dysfunction,  such  as  in  chronic  heart  failure,
hypertension,  renal  failure,  diabetes,  and  pulmonary
hypertension  [2-4].  ADMA  is  also  related  to  endothelial
dysfunction in diabetic complications. Our previous studies
suggested  that  PRMT-1-  and  DDAH-induced  ADMA
upregulation was involved in reactive oxygen species (ROS)-
and  renin-angiotensin  system  (RAS)-mediated  diabetic
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retinopathy (DR), which may be a novel mechanism for the
development  or  progression  of  DR  [5].  Angiotensin-
converting enzyme inhibitor (ACEI), angiotensin II receptor
blocker (ARB), or antioxidants can be used to reduce ROS
production  and  lower  ADMA  concentrations,  thus
ameliorating  endothelial  dysfunction  and  improving
prognosis in DR [5].
DR is a leading cause of acquired visual impairment in
working-age adults in developed countries [6]. The precise
mechanism  underlying  the  progression  of  DR  remains
unclear. Several biochemical abnormalities, such as excessive
nonenzymatic glycation [7], activation of the aldose reductase
pathway [8], activation of protein kinase C [9], and oxidative
stress [10], have been identified as being involved in the
pathogenesis  of  DR.  Oxidative  stress  induced  by
hyperglycemia is thought to play a significant role in DR and
to contribute to endothelial dysfunction [11]. Increases in
ROS level are correlated with increased leukocyte adhesion
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332to the retinal vasculature (leukostasis) and breakdown of the
blood-retinal barrier (BRB) [12,13]. Breakdown of the BRB
and leukostasis are hallmarks of DR. Increased leukostasis in
the early stages of DR occurs through the upregulation of
intercellular adhesion molecule-1 (ICAM-1) [14]. Diabetes-
induced  BRB  breakdown  is  associated  with  reduced
expression of the tight-junction protein occludin, and with its
redistribution within the retinal vascular endothelium [15].
Recent  studies  indicated  that  ADMA  regulates
endothelial  permeability  and  endothelial  barrier  function
[16]. The present study was performed to investigate whether
ADMA  affects  cell  proliferation,  ROS  production,  cell
permeability, ICAM-1, and tight-junction protein occludin
expression  in  bovine  retinal  capillary  endothelial  cells
(BRCECs). Moreover, we observed the interfering effects of
ACEI, ARB, and antioxidants on the above changes, to assess
the role of ADMA in retinal capillary endothelial permeability
and endothelial barrier function.
METHODS
Cell culture: BRCECs were cultured as described previously
[17].  Briefly,  BRCECs  were  cultured  in  endothelial  cell
medium  (ECM;  ScienCell  Research  Labs,  Carlsbad,  CA)
consisting  of  5%  fetal  bovine  serum,  1%  endothelial  cell
growth supplement, and 1% penicillin/streptomycin solution.
Endothelial cells at passage 3–5 were used in the following
experiments,  including  the  cell  proliferation  assay,
examination  of  ROS  levels,  permeability  assay,  western
blotting analysis, and quantitative real-time (RT)-PCR. The
cells were washed when at 80% confluence and were cultured
overnight with endothelial cell basal medium, consisting of
0.4%  fetal  bovine  serum  and  1%  penicillin/streptomycin
solution. The cells were then incubated with 100 μM ADMA
(Sigma, St. Louis, MO) and 100 μM ADMA plus 10 μM
benazepril  (Sigma),  10  μM  telmisartan  (Sigma),  10  μM
diphenyliodonium (DPI, an reduced form of nicotinamide-
adenine dinucleotide phosphate [NADPH] oxidase inhibitor;
Sigma), or 10 mM N-acetyl-L-cysteine (NAC, an antioxidant
and free radical scavenger; Sigma). The control group was
cultured in endothelial cell basal medium, consisting of 0.4%
fetal bovine serum and 1% penicillin/streptomycin solution.
Cells were harvested after 24 h for western blotting analysis,
quantitative  RT–PCR  analysis,  and  examination  of  ROS
levels.
Cell  proliferation  assay:  Cell  proliferation  assay  was
performed using the novel tetrazolium compound, 3-(4, 5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium  (MTS),  and  the  electron-
coupling  reagent,  phenazine  ethosulfate  (PES).  PES  has
enhanced chemical stability, which allows it to be combined
with MTS to form a stable solution. This convenient “one
solution”  format  is  an  improvement  over  the  traditional
method, where phenazine methosulfate (PMS) is used as the
electron-coupling  reagent,  and  PMS  solution  and  MTS
solution  are  supplied  separately.  The  MTS  tetrazolium
compound (Owen’s reagent) is bioreduced by cells into a
colored formazan product that is soluble in tissue culture
medium.  This  conversion  is  presumably  accomplished  by
NADPH or reduced form of nicotinamide-adenine dinucleotid
(NADH),  produced  by  dehydrogenase  enzymes  in
metabolically  active  cells  [18].  The  quantity  of  formazan
product, as determined by measuring the absorbance at 490
nm, is directly proportional to the number of living cells in the
culture. Endothelial cells were plated in 96-well culture plates
at an optimal density of 1×105 cells/ml with 100 μl of culture
medium  per  well.  After  3  days,  cells  were  cultured  with
endothelial cell basal medium, consisting of 0.4% fetal bovine
serum and 1% penicillin/streptomycin solution, overnight.
The cells were then incubated with 10 μM, 50 μM, 100 μM,
and 200 μM ADMA for 24–72 h. Then, 20 μl of CellTiter
96® AQueous One Solution Reagent (Promega, Madison, WI)
were  pipetted  into  each  well  of  the  96-well  assay  plates
containing the samples in 100 μl of culture medium. The plates
were incubated at 37 °C for 1–4 h in a humidified, 5% CO2
atmosphere.  The  optical  density  of  each  sample  was
determined immediately on an enzyme linked immunosorbent
assay (ELISA) microplate reader (Wallac 1420; PerkinElmer,
Waltham, MA) at 490 nm. Samples were tested in duplicate.
The corrected absorbance at 490 nm (y-axis) was plotted
against the incubation time of cells with ADMA (x-axis).
Examination  of  reactive  oxygen  species  levels  in  bovine
retinal capillary endothelial cells: Intracellular ROS levels in
BRCECs were determined using CM-H2DCFDA (Invitrogen,
Carlsbad,  CA).  Confluent  BRCECs  in  6-well  plates  were
collected, centrifuged, washed with phosphate-buffered saline
(PBS),  which  contained  1.06  mM  monobasic  potassium
phosphate, 155.17 mM sodium chloride, and 2.97 mM dibasic
sodium phosphate and incubated with 10 μM CM-H2DCFDA
at  37  °C  for  30  min.  BRCECs  incubated  with  PBS  and
dimethyl sulfoxide served as negative controls. The levels of
fluorescence were immediately determined by flow cytometry
(XL-4; Beckman-Coulter, Fullerton, CA).
Permeability assay: BRCECs (1×105 cells/ml) were plated in
double-chamber  tissue  culture  plates  (Transwell,  24-well
filter chambers with 0.4 μm pore size membrane; Costar,
Coring Inc., New York, NY). At 80% confluence, cells were
cultured with endothelial cell basal medium, consisting of
0.4%  fetal  bovine  serum  and  1%  penicillin/streptomycin
solution,  overnight.  The  cells  were  then  incubated  with
100  μM  ADMA,  and  100  μM  ADMA  plus  benazepril
(10 μM), telmisartan (10 μM), DPI (10 μM), or NAC (10 mM)
for 24 h. Controls were cultured with endothelial cell basal
medium,  consisting  of  0.4%  fetal  bovine  serum  and  1%
penicillin/streptomycin solution.
For the permeability assay, horseradish peroxidase (HRP,
40 kDa; Sigma) was added to the upper chambers at a final
concentration of 50 μg/ml. Aliquots of 5 μl were collected
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333from the lower chamber after 15 min, 30 min, 45 min, and 1
h. The concentrations of HRP were determined in 5 μl aliquots
added  to  195  μl  of  freshly  made  substrate  (o-
phenylenediamine, 400 μg/ml in 0.05 mM citric acid and
0.1 mM phosphate, with 0.012% hydrogen peroxidase, pH
5.0). The reaction was terminated by the addition of 50 μl of
0.3 mM sulfuric acid after 15 min, and optical density was
determined using a microplate reader (PerkinElmer, Boston,
MA) at 490 nm. A standard curve was prepared from HRP
serial dilutions in each experiment, and the samples were
diluted such that all readings fell within the linear range of the
standard  curve.  The  readings  for  each  tracer  were  then
converted to nanograms per milliliter by comparison with
standard curves generated using tracer samples taken at time
zero. Permeability was calculated as flux: (ml/cm2)=(X)B/
[(Y)i*A], where (X)B (μg) is the level of HRP in the lower
chamber, (Y)i (μg/ml) is the concentration of HRP in the upper
chamber, and A (cm2) is the effective surface area of the insert.
Each experiment was repeated at least three times.
Western  blotting  analysis  of  intercellular  adhesion
molecule-1 and occludin expression: Cells were sonicated in
Tris-buffered  saline  (TBS)  containing  protease  inhibitors.
After sonication, the lysate was centrifuged (12,000× g, 15
min, 4 °C) and the supernatant was transferred to a fresh tube.
The protein content was quantified with a Pierce protein assay
kit (Pierce, Rockford, IL). Samples of equal concentration
(80 μg/lane) were separated on 10% sodium dodecyl sulfate
polyacrylamide  gel  electropheresis  (SDS–PAGE)  and
transferred onto polyvinylidene difluoride (PVDF) transfer
membranes (Immobilon P; Millipore, Billerica, MA). The
membranes were blocked in TBS containing 0.1% Tween-20
and  5%  nonfat  dry  milk  for  2  h,  followed  by  overnight
incubation at 4 °C with polyclonal antibodies for ICAM-1
(Abcam, Cambridge, UK) or occludin (Invitrogen, Carlsbad,
CA) at 1:1,000 dilution. After rinsing in TBS with Tween-20
(TBST), the membranes were incubated for 2 h with an HRP-
conjugated secondary antibody against mouse IgG (Dako,
Glostrup, Denmark) in a 1:1,000 dilution and rinsed with
TBST,  and  bands  on  the  blots  were  then  detected  using
SuperSignal West Pico Chemiluminescent Substrate (Pierce).
The  densities  of  the  bands  were  analyzed  using  Gel-Pro
Analyzer  (Media  Cybernetics,  Bethesda,  MD).  The
expression  of  β-actin  (1:5000;  monoclonal  anti-β-actin;
Sigma) was used as an internal control.
TABLE 1. PRIMER SEQUENCES FOR QUANTITATIVE RT–PCR.
Gene Probe (5′-3′) Forward primer (5′-3′) Reverse primer (5′-3′)
ICAM-1 CCACGGAGCAGCACCACGGT GTGACCAGCCCAAGTTGT TCCCGTTTCAGCTCCTTCT
occludin AAACCGCTTGTCATTCACTTTGCCA GGGACAAGGAACACATTTATGAT TGGATTTATAGGAAGACTCTGGAT
18S rRNA CGCCTGCTGCCTTCCTTGGATGTG AGTCGCCGTGCCTACCAT CGGGTCGGGAGTGGGTAAT
Figure 1. Cell proliferation analysis of bovine retinal capillary endothelial cells. Cell proliferation was significantly inhibited by asymmetric
dimethylarginine (ADMA) for 24–72 h. In group A, bovine retinal capillary endothelial cells (BRCECs) were cultured in endothelial cell
medium (ECM) with 0.4% fetal bovine serum (FBS). In groups B throught E, BRCECs were cultured in ECM with 0.4% FBS plus 10 μM,
50 μM, 100 μM, or 200 μM ADMA. Results are expressed as absorbance at 490 nm and represent means±SEM, n=8: *p<0.05 versus group
A, **p<0.01 versus group A, #p<0.05 versus group B, ##p<0.01 versus group B, +p<0.05 versus group C, ++p<0.01 versus group C, &p<0.05
versus group D, &&p<0.01 versus group D.
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334Quantitative  real-time  PCR:  After  removal  of  the  culture
medium, cells were washed with PBS, then combined with the
TRIzol  reagent  (Invitrogen).  Extracted  RNA  was  then
quantified spectrophotometrically at 260 nm and integrity was
assessed by agarose-formaldehyde gel electrophoresis. Total
RNA samples were treated with DNase I (RQ1; Promega) and
then reverse transcribed using a ReverTra Ace RT–PCR kit
(Toyobo,  Osaka,  Japan)  according  to  the  manufacturer’s
instructions. Primers were designed using DNA Star software
according to the guidelines supplied with the software. The
primer sequences were described in Table 1.
To exclude DNA interference, primers were designed to
span at least one intron. To quantify the amounts of specific
mRNA (mRNA) in the samples, we generated a standard
curve for each run using a plasmid (pGEM-T Easy Vector;
Promega) containing the gene of interest as a standard. This
enabled standardization of the initial mRNA content of cells
relative  to  the  amount  of  18S  rRNA.  PCR  assays  were
performed  using  SLAN®  RT–PCR  system  (Hongshi,
Shanghai,  China).  The  quantitative  RT–PCR  solution
consisted of 2.0 μl of diluted RT–PCR product, 0.5 μl of each
primer pair, 25 μl of RT–PCR Master Mix (Toyobo, Osaka,
Japan), 1.0 μl of fluorogenic probe, and 10 μl of PCR-grade
water.  The  amplification  conditions  for  ICAM-1  and
occluding were as follows: 94 °C for 3 min, followed by 40
cycles of 94 °C for 20 s, 55 °C for 20 s, and 72 °C for 20 s.
The results of quantitative RT–PCR were analyzed using the
relative standard curve method with the SLAN software (v.
5.0). Values were normalized relative to the relative amounts
of 18S rRNA, which were obtained from a similar standard
curve.
Statistical  analysis:  All  results  are  expressed  as  means
±standard  deviation  unless  otherwise  indicated.  Statistical
evaluation was performed with the SPSS software (ver. 14.0
for  Windows;  SPSS,  Chicago,  IL)  using  ANOVA  with
multiple  comparisons  between  groups  and  Pearson’s
correlation test. In all analyses, p<0.05 was taken to indicate
statistical significance.
RESULTS
Cell proliferation assay: Cell proliferation was significantly
inhibited after incubation of BRCECs with 10 μM, 50 μM,
100 μM, or 200 μM ADMA for 24–72 h. Moreover, cell
proliferation  showed  more  significant  inhibition  with
increasing ADMA concentration (Figure 1).
Reactive oxygen species determination: After incubation with
ADMA (100 μM) for 24 h, intracellular ROS generation in
BRCECs was significantly increased, compared with those
incubated in normal medium (p<0.01). The increased ROS
production induced by ADMA was markedly inhibited by
Figure 2. Intracellular reactive oxygen species generation in bovine retinal capillary endothelial cells for 24 h, as determined using the
fluorescent probe CM-H2DCFDA. symmetric dimethylarginine (ADMA) increased intracellular reactive oxygen species (ROS) generation
in bovine retinal capillary endothelial cells (BRCECs). The increased reactive oxygen species (ROS) production induced by asymmetric
dimethylarginine (ADMA) was markedly inhibited by benazepril, telmisartan, diphenyliodonium, or N-acetyl-L-cysteine. In group C, BRCECs
were cultured in endothelial cell medium with 0.4% fetal bovine serum. In group A, BRCECs were cultured in endothelial cell medium with
0.4% fetal bovine serum plus ADMA (100 μM). In group “A+B,” BRCECs were cultured in the same media as A and 10 μM benazepril. In
group “A+T,” BRCECs were cultured in the same media as A and 10 μM telmisartan. In group “A+D,” BRCECs were cultured in the same
media as A and 10 μM diphenyliodonium. In group “A+N,” BRCECs were cultured in the same media as group A and 10 mM N-acetyl-L-
cysteine (mean±SD, n=3). **p<0.01 versus group C, ##p<0.01 versus group A.
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335benazepril (10 μM), telmisartan (10 μM), DPI (10 μM), or
NAC (10 mM; all p<0.01; Figure 2).
Permeability assay: ADMA (100 μM) significantly increased
HRP permeability in BRCECs. Treatment with benazepril
(10  μM)  and  NAC  (10  mM)  for  15  min  decreased  HRP
permeability in BRCECs exposed to ADMA (100 μM). The
increase  in  permeability  by  ADMA  (100  μM)  was
significantly  downregulated  by  benazepril  (10  μM),
telmisartan (10 μM), DPI (10 μM), or NAC (10 mM) for 30
min, 45 min, and 1 h (Figure 3).
Western blotting analysis: Western blotting analysis indicated
that  exposure  to  ADMA  (100  μM)  for  24  h  markedly
upregulated  ICAM-1  protein  expression  in  BRCECs
(p<0.01). Treatment with telmisartan (10 μM), DPI (10 μM),
or NAC (10 mM) downregulated ICAM-1 protein expression
in BRCECs exposed to ADMA (100 μM; p<0.01). Benazepril
(10 μM) had no effect on ICAM-1 expression (p>0.05; Figure
4).
Experiments  performed  in  vitro  also  showed  that
exposure  to  ADMA  (100  μM)  for  24  h  significantly
downregulated  occludin  protein  expression  in  BRCECs
(p<0.01). Treatment with benazepril (10 μM) or telmisartan
(10 μM) upregulated occludin protein expression in BRCECs
exposed to ADMA (p<0.01), while DPI (10 μM) and NAC
(10 mM) had no effect on occludin expression (p>0.05; Figure
5).
Quantitative  real-time  PCR  analysis:  ICAM-1  mRNA
expression in BRCECs was markedly upregulated following
exposure to ADMA (100 μM) for 24 h (p<0.01). Benazepril
(10 μM), telmisartan (10 μM), DPI (10 μM), or NAC (10 mM)
downregulated  ICAM-1  mRNA  expression  in  BRCECs
exposed to ADMA (100 μM; p<0.01; Figure 6).
Occludin  mRNA  expression  in  BRCECs  was
downregulated when cells were exposed to ADMA (100 μM)
for  24  h  (p<0.05).  Treatment  with  benazepril  (10  μM),
telmisartan (10 μM), or DPI (10 μM) upregulated the occludin
mRNA  level  in  BRCECs  exposed  to  ADMA  (p<0.05).
However, NAC (10 mM) had no effect on the occludin mRNA
level (p>0.05; Figure 7).
DISCUSSION
Kakimoto  and  Akazawa  [19]  first  isolated  and  described
ADMA  from  human  urine  in  1970.  Since  their  initial
observation, ADMA has been shown to represent a novel risk
factor  for  the  development  of  endothelial  dysfunction.
Oxidative stress has been shown to increase the activity of
arginine-methylating  and  ADMA-degrading  enzymes,
leading to increased ADMA concentrations; moreover, high
ADMA levels further contribute to the vascular oxidative
stress  burden  in  a  positive  feedback  fashion  [20,21].  As
reported previously, BRCECs incubated in the presence of
high  glucose  concentrations  showed  elevated  ROS
production,  PRMT-1  expression,  reduced  DDAH  activity,
and DDAH II expression, and increased the accumulation of
Figure  3.  Horseradish  peroxidase  (HRP)  permeability  assay  of  bovine  retinal  capillary  endothelial  cells  (BRCECs).  Asymmetric
dimethylarginine (ADMA) significantly increased HRP permeability in BRCECs. Treatment with benazepril and NAC for 15 min decreased
HRP  permeability  in  BRCECs.  The  permeability  increase  by  ADMA  was  significantly  downregulated  by  benazepril,  telmisartan,
diphenyliodonium (DPI), or N-acetyl-L-cysteine (NAC) for 30 min, 45 min, and 1 h. The group C bars are that BRCECs were cultured in
endothelial cell medium (ECM) with 0.4% FBS. In group A, BRCECs were cultured in ECM with 0.4% FBS plus ADMA (100 μM). In group
“A+B,” BRCECs were cultured in the same media as A and 10 μM benazepril. Group “A+T” was the same as for group A and 10 μM
telmisartan. In group “A+D,” BRCECs were cultured in the same media as group A and 10 μM DPI. In group “A+N,” BRCECs were cultured
in the same media as group A and 10 mM NAC (mean±SD, n=3). *p<0.05 versus group C, **p<0.01 versus group C, #p<0.05 versus group
A, ##p<0.01 versus group A.
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336ADMA in a conditioned medium [5]. In the present study, we
found that ADMA increased intracellular ROS generation in
BRCECs. Thus, we propose that ADMA is not only a marker,
but also a producer of oxidative stress, under high-glucose
conditions.
There have been many recent studies regarding the effects
of  different  therapeutic  interventions  on  ADMA  plasma
concentrations. ACEI and ARB have been shown to reduce
the levels of ADMA and improve endothelial dysfunction in
human essential hypertension and diabetes mellitus [22-24].
Although the mechanisms of the beneficial effects of ACEI
and ARB remain obscure, ADMA is known to upregulate
several  components  of  microvascular  RAS,  leading  to
increased production of angiotensin II, which then activates
NADPH oxidase and increases ROS production [25]. ADMA
improves the p38 mitogen-activated protein kinase activity in
human coronary artery endothelial cells, which may provide
a  link  between  ADMA  and  RAS,  because  ACE  protein
expression has been shown to be regulated by p38 mitogen-
activated protein kinase [26,27]. In the present study, the
NADPH oxidase inhibitor DPI or the free-radical scavenger
NAC  decreased  intracellular  ROS  generation  in  BRCECs
incubated with ADMA. Benazepril or telmisartan had effects
similar to those from DPI and NAC, indicating that they may
also exert their effects through the oxidase pathway.
It has been reported that ADMA regulates endothelial
permeability  and  endothelial  barrier  function.  Several
possible  mechanisms  have  been  proposed  to  explain  the
effects of ADMA on endothelial barrier function. A previous
study indicated that ADMA increased pulmonary endothelial
permeability both in vitro and in vivo, and that this effect was
mediated by nitric oxide, acting via protein kinase G and
independent  of  ROS  formation  [16].  Others  have
demonstrated that ADMA compromises the integrity of the
glomerular filtration barrier by altering the bioavailability of
nitric  oxide  and  superoxide,  and  that  nitric  oxide  (NO)-
independent activation of soluble guanylyl cyclase preserves
the integrity of this barrier under conditions of NO depletion
[28].  ADMA  markedly  downregulated  connexin43
expression  and  damaged  gap  junction  function  in  human
umbilical vein endothelial cells by increasing the production
of intracellular ROS and inducing phosphorylation of p38
MAPK [29]. However, to date, the role of ADMA in the BRB
has not been studied.
The BRB, an important ocular barrier, consists of two
components: the inner and outer BRB. The inner BRB is
formed by retinal microvascular endothelial cells with tight
junctions between them. The normal inner BRB is determined
by the homeostasis of retinal microvessels, and plays a critical
role  in  normal  visual  function.  Enhanced  retinal  vascular
permeability  has  been  shown  to  aggravate  microvascular
endothelial  cell  damage  and  capillary  nonperfusion  [30].
Several studies linked inflammation to vascular leakage in
diabetic retinopathy. Leukocytes adhere to the retinal vascular
endothelium early in diabetic retinopathy, the onset of which
occurs  before  the  development  of  any  clinical  pathology
Figure 4. Intercellular adhesion molecule-1 (ICAM-1) protein expression in bovine retinal capillary endothelial cells. A: western blotting
analysis showing the presence of ICAM-1 protein in bovine retinal capillary endothelial cells (BRCECs). B: Results of statistical analysis of
protein levels relative to β-actin. Asymmetric dimethylarginine (ADMA) markedly upregulated ICAM-1 protein expression in BRCECs.
Telmisartan, diphenyliodonium (DPI), or N-acetyl-L-cysteine (NAC) downregulated ICAM-1 protein expression in BRCECs exposed to
ADMA. Benazepril had no effect on ICAM-1 expression. In group C, BRCECs wrre cultured in endothelial cell medium (ECM) with 0.4%
fetal bovine serum (FBS). In group A, BRCECs were cultured in ECM with 0.4% FBS plus ADMA (100 μM). In group “A+B,” BRCECs
were cultured in the same media as A and 10 μM benazepril. In group “A+T,” BRCECs were cultured in the same media as group A and 10
μM telmisartan. In group “A+D,” BRCECs were cultured in the same media as group A and 10 μM DPI. In group “A+N,” BRCECs were
cultured in the same media as A and 10 mM NAC (mean±SD, n=3). **p<0.01 versus C, ##p<0.01 versus group A.
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337[14].  Further,  leukocyte  adhesion  coincides  with  the
development of BRB breakdown and capillary nonperfusion
[14]. The expression of ICAM-1 is upregulated in DR, and the
Figure 6. The statistical analysis results of bovine retinal capillary
endothelial  cells  (BRCECs)  intercellular  adhesion  molecule-1
(ICAM-1)  gene  expression  relative  to  18S  rRNA  for  24  h.
Asymmetric  dimethylarginine  (ADMA)  markedly  upregulated
ICAM-1  mRNA  expression  in  BRCECs  for  24  h.  Benazepril,
telmisartan, diphenyliodonium (DPI), or N-acetyl-L-cysteine (NAC)
downregulated ICAM-1 mRNA expression in BRCECs exposed to
ADMA.  In  group  C,  BRCECs  were  cultured  in  endothelial  cell
medium (ECM) with 0.4% fetal bovine serum (FBS). In group A,
BRCECs were cultured in ECM with 0.4% FBS plus ADMA (100
μM). “A+B” represents same as for group A and 10 μM benazepril.
In group “A+T,” BRCECs were cultured in the same media as group
A and 10 μM telmisartan. In group “A+D,” BRCECs were cultured
in the same media as group A and 10 μM DPI. In group “A+N,”
BRCECs were cultured in the same media as group A and 10 mM
NAC (mean±SD, n=3). **p<0.01 versus group C, ##p<0.01 versus
group A.
specific  inhibition  of  ICAM-1  prevents  diabetic  retinal
leukocyte adhesion and BRB breakdown [14,31,32].
In this study, ADMA significantly increased BRCEC
permeability within 1 h and was strongly involved in reducing
Figure 7. Results of statistical analysis of occludin gene expression
relative to 18S rRNA in bovine retinal capillary endothelial cells
(BRCECs)  for  24  h.  ADMA  downregulated  occludin  mRNA
expression  in  BRCECs  for  24  h.  Benazepril,  telmisartan,  or
diphenyliodonium  (DPI)  upregulated  occludin  mRNA  level.
However,  N-acetyl-L-cysteine  (NAC)  had  no  effect  on  occludin
mRNA level. In group C, BRCECs were cultured in endothelial cell
medium (ECM) with 0.4% fetal bovine serum (FBS). In group A,
BRCECs were cultured in ECM with 0.4% FBS plus ADMA (100
μM). In group “A+B,” BRCECs were cultured in the same media as
group A and 10 μM benazepril. In “A+T,” BRCECs were cultured
in the same media as group A and 10 μM telmisartan. In group “A
+D,” BRCECs were cultured in the same media as group A and 10
μM DPI. In group “A+N,” BRCECs were cultured in the same media
as group A and 10 mM NAC (mean±SD, n=3). *p<0.05 versus group
C, #p<0.05 versus group A.
Figure 5. Occludin protein expression in bovine retinal capillary endothelial cells. A: western blotting analysis showing the presence of occludin
protein in bovine retinal capillary endothelial cells (BRCECs). B: The results of statistical analysis of protein level relative to β-actin.
Asymmetric dimethylarginine (ADMA) significantly downregulated occludin protein expression in BRCECs. Benazepril and telmisartan
upregulated protein expression of occludin in BRCECs exposed to ADMA. However, diphenyliodonium (DPI) and N-acetyl-L-cysteine (NAC)
had no effect on occludin expression. In group C, BRCECs were cultured in ECM with 0.4% fetal bovine serum (FBS). In group A, BRCECs
were cultured in ECM with 0.4% FBS plus ADMA (100 μM). Group “A+B” represents same as for group A and 10 μM benazepril. Group
“A+T” represents same as for group A and 10 μM telmisartan. Group “A+D” represents same as for group A and 10 μM DPI. Group “A+N”
represents same as for group A and 10 mM NAC (mean±SD, n=3). **p<0.01 versus group C, ##p<0.01 versus group A.
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338the  levels  of  the  tight-junction  protein  occludin  and
upregulation of ICAM-1 expression in BRCECs. ACEI, ARB,
or antioxidants significantly downregulated cell permeability
increased by ADMA at 30 min, 45 min, and 1 h. Furthermore,
we observed that benazepril, telmisartan, and the antioxidant
DPI reversed the effects of ADMA on occludin and ICAM-1
expression. Based on our findings, we hypothesize that the
mechanism of ADMA damage to the BRB is partly mediated
by ROS and/or RAS pathways.
In summary, ADMA can inhibit BRCEC proliferation,
increase  intracellular  ROS  generation,  increase  cell
permeability and in BRCECs, can reduce levels of the tight-
junction protein occludin and increase ICAM-1 expression.
Further  studies  are  required  to  determine  the  precise
mechanisms underlying the effects of ADMA in diabetes-
induced BRB breakdown and the roles of ACEI, ARB, and
antioxidants  in  the  control  of  retinal  endothelial  barrier
function under diabetic conditions.
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